精准医学与ARDS治疗效应异质性
ARDS是临床异质性综合征而非单一疾病,这种异质性部分解释了治疗研究难以显效的原因。近期研究识别出不同亚表型,其对特定治疗的反应可能不同,即治疗效应异质性。本综述总结了识别亚表型的研究,并讨论其如何改变那些通常被认为对ARDS患者无总体益处的试验疗法的效应。
要点
- ARDS是异质性综合征,亚表型对治疗反应不同。
- 治疗效应异质性可解释既往试验总体无益的结果。
- 识别亚表型对ARDS临床管理有重要意义。
核心结论
- ARDS是临床异质性综合征而非单一疾病,识别亚表型与治疗效应异质性对临床管理有重要意义。
研究设计与样本
- 综述,总结识别ARDS不同亚表型的研究并讨论其对试验疗法效应的影响。
主要发现
- 不同亚表型对特定治疗的反应可能不同,即存在治疗效应异质性。
- 治疗效应异质性可部分解释为何多项ARDS疗法试验未显示总体益处。
临床怎么用
- 临床管理中应认识ARDS不同亚表型及治疗效应异质性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ARDS is a clinically heterogeneous syndrome, rather than a distinct disease. This heterogeneity at least partially explains the difficulty in studying treatments for these patients and contributes to the numerous trials of therapies for the syndrome that have not shown benefit. Recent studies have identified different subphenotypes within the heterogeneous patient population. These different subphenotypes likely have variable clinical responses to specific therapies, a concept known as heterogeneity of treatment effect. Recognizing different subphenotypes and heterogeneity of treatment effect has important implications for the clinical management of patients with ARDS. This review presents studies that have identified different subphenotypes and discusses how they can modify the effects of therapies evaluated in trials that are commonly considered to have shown no overall benefit in patients with ARDS.
引用
- Khan YA, Fan E, Ferguson ND, et al. Precision Medicine and Heterogeneity of Treatment Effect in Therapies for ARDS. Chest. 2021. PMID: 34270967. doi:10.1016/j.chest.2021.07.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。